2007•International Journal of CardiologyRequires access

Both levosimendan and dobutamine treatments result in significant reduction of NT-proBNP levels, but levosimendan has better and prolonged neurohormonal effects than dobutamine

Yüksel Çavuşoğlu, Müjgan Tek, Alparslan Birdane, Necmi Ata, Canan Demirüstü, Bülent Görenek, Ahmet Ünalır, Bilgin Timuralp

Open publisher page 15 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 15 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Levosimendan, Dobutamine, Medicine, Cardiology, Internal medicine, Ejection fraction, Inotrope, Hemodynamics

Back to paper search Browse research topics Original source

Both levosimendan and dobutamine treatments result in significant reduction of NT-proBNP levels, but levosimendan has better and prolonged neurohormonal effects than dobutamine — Research Paper | ScholarLens